Accelerated Drug Approvals: FDA May Involve NCI In Confirmatory Trials
Executive Summary
The National Cancer Institute could have a role in ensuring that confirmatory trials are conducted for cancer drugs that are given accelerated approval, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said
You may also be interested in...
“Underpowered” Cancer Trials Are Becoming “Major Problem” – FDA’s Pazdur
Cancer drug trials that are statistically "underpowered" because of their small size are becoming a "major problem," FDA Oncologic Drug Products Division Director Richard Pazdur, MD, told a joint American Society of Clinical Oncology/FDA workshop April 15 in Alexandria, Va
Cancer Drug Confirmatory Trials Should Be Initiated Early, FDA Says
FDA is urging sponsors of cancer drugs undergoing accelerated approval to initiate confirmatory studies early to avoid problems in completing trials often seen after approval
Accelerated Approval Needs Enforcement Mechanism For Confirmatory Trials
FDA needs to create an enforcement mechanism to ensure that companies with anticancer agents awarded accelerated approval complete confirmatory trials to show actual clinical benefit, the Oncologic Drugs Advisory Committee agreed